Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697072 · ClinicalTrials.gov registry record · Phase 3
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT01697072: Clinical Trial Phase 3 study, sponsored by Amgen.
NCT01697072 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 609 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01697072, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Primary Outcome
To determine if the treatment of rilotumumab in combination with ECX significantly improves overall survival in subjects with unresectable locally advanced or metastatic MET positive gastric or GEJ cancer
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- OTHER Placebo
- DRUG Epirubicin
- DRUG Rilotumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Why NCT01697072 stopped before completion
NCT01697072 is an interventional study that assigns participants to a tested intervention. The registered 609 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT01697072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01697072 about?
NCT01697072 is a clinical study titled "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma". This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
What is the current status of trial NCT01697072?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2012-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01697072?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Placebo (OTHER), Epirubicin (DRUG), Rilotumumab (DRUG).
Who is sponsoring clinical trial NCT01697072?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01697072's enrollment target sits among peer trials
609 602nd of 2000 higher than 1,398 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia